Compare OI & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OI | IMNM |
|---|---|---|
| Founded | 1903 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | N/A | 2020 |
| Metric | OI | IMNM |
|---|---|---|
| Price | $15.43 | $19.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | $16.29 | ★ $26.89 |
| AVG Volume (30 Days) | ★ 2.3M | 1.1M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,455,000,000.00 | $9,679,000.00 |
| Revenue This Year | $1.41 | N/A |
| Revenue Next Year | $1.99 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.23 | $5.15 |
| 52 Week High | $16.04 | $20.75 |
| Indicator | OI | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 73.59 | 58.01 |
| Support Level | $13.01 | $18.87 |
| Resistance Level | $14.60 | $20.80 |
| Average True Range (ATR) | 0.49 | 1.22 |
| MACD | 0.17 | -0.03 |
| Stochastic Oscillator | 99.46 | 67.17 |
O-I Glass is the world's largest manufacturer of glass bottles; 70% of its revenue comes from outside the United States. O-I has a leading position in key markets such as Europe, North America, and Brazil. Beer is the primary end market for O-I's glass bottles, which are also used for wine, soda, spirits, condiments, and food. O-I is looking to maintain or expand its dominant positions in Europe, North America, and South America.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.